Document Detail

Cholesterol lowering with bile salt hydrolase-active probiotic bacteria, mechanism of action, clinical evidence, and future direction for heart health applications.
MedLine Citation:
PMID:  23350815     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: Cardiovascular diseases (CVD) are the leading cause of global mortality and morbidity. Current CVD treatment methods include dietary intervention, statins, fibrates, niacin, cholesterol absorption inhibitors, and bile acid sequestrants. These formulations have limitations and, thus, additional treatment modalities are needed. Probiotic bacteria, especially bile salt hydrolase (BSH)-active probiotic bacteria, have demonstrated cholesterol-lowering efficacy in randomized controlled trials.
AREAS COVERED: This review describes the current treatments for CVD and the need for additional therapeutics. Gut microbiota etiology of CVD, cholesterol metabolism, and the role of probiotic formulations as therapeutics for the treatment and prevention of CVD are described. Specifically, we review studies using BSH-active bacteria as cholesterol-lowering agents with emphasis on their cholesterol-lowering mechanisms of action. Potential limitations and future directions are also highlighted.
EXPERT OPINION: Numerous clinical studies have concluded that BSH-active probiotic bacteria, or products containing them, are efficient in lowering total and low-density lipoprotein cholesterol. However, the mechanisms of action of BSH-active probiotic bacteria need to be further supported. There is also the need for a meta-analysis to provide better information regarding the therapeutic use of BSH-active probiotic bacteria. The future of BSH-active probiotic bacteria most likely lies as a combination therapy with already existing treatment options.
Mitchell L Jones; Catherine Tomaro-Duchesneau; Christopher J Martoni; Satya Prakash
Related Documents :
12529505 - Reduction of cholera in bangladeshi villages by simple filtration.
24714785 - Evaluation of hypocholesterolemic effect and antioxidant activity of boops boops protei...
23479335 - Association between lipids, lipoproteins composition of hdl particles and triglyceride-...
21346625 - Salt-induced renal injury in shrs is mediated by at1 receptor activation.
15466985 - Dietary factors and risk of non-hodgkin lymphoma by histologic subtype: a case-control ...
21784375 - The relationship between body mass index and the variation in plasma levels of triglyce...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2013-01-28
Journal Detail:
Title:  Expert opinion on biological therapy     Volume:  13     ISSN:  1744-7682     ISO Abbreviation:  Expert Opin Biol Ther     Publication Date:  2013 May 
Date Detail:
Created Date:  2013-04-08     Completed Date:  2013-09-25     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  101125414     Medline TA:  Expert Opin Biol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  631-42     Citation Subset:  IM    
Micropharma Ltd, 141 avenue du President Kennedy, UQAM Biological Sciences Building, 5th Floor, Suite 5569 Montreal, Quebec, H2X 3Y7, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amidohydrolases / chemistry*
Anticholesteremic Agents*
Cholesterol / metabolism*
Gastrointestinal Tract / microbiology
Heart Diseases / microbiology,  prevention & control*
Hypercholesterolemia / drug therapy
Hyperlipidemias / drug therapy
Probiotics / chemistry*,  therapeutic use*
Grant Support
MPO 64308//Canadian Institutes of Health Research
Reg. No./Substance:
0/Anticholesteremic Agents; 57-88-5/Cholesterol; EC 3.5.-/Amidohydrolases; EC hydrolase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Collagen/?(1) integrin interaction is required for embryoid body formation during cardiogenesis from...
Next Document:  Zwitterions and Unobserved Intermediates in Organocatalytic Diels-Alder Reactions of Linear and Cros...